Payvandi, F., Wu, L., Naziruddin, S.D., Haley, M., Parton, A., Schafer, P.H., Chen, R.S., Muller, G.W., Hughes, C.C. and Stirling, D.I. (2005) Immunomo- dulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. Journal of Interferon & Cytokine Research, 25, 604-616. doi:10.1089/jir.2005.25.604

has been cited by the following article:

• TITLE: Efficacy of IMOD in the treatment of oral lichen planus—Efficacy of IMOD in oral lichen planus

  AUTHORS: Farzaneh Agha-Hosseini, Iraj Mirzaii-Dizgah, Mohammad Abdollahi, Neda Akbari-Gillani

  KEYWORDS: Oral Lichen Planus; IMOD; TNF-α

  JOURNAL NAME: Open Journal of Stomatology, Vol.1 No.2, July 1, 2011

  ABSTRACT: Objectives: Oral lichen planus (OLP) is a chronic, immunologically mediated, mucocutaneous disorder. A wide range of topical and systemic therapies have been used in the treatment of OLP. The efficacy of IMOD (an Iranian new immunomodulator drug, con- taining selenium, carotene, and flavonoids) in the management of oral lichen planus was evaluated. Study design: In a before-after clinical trial study, thirty patients (21 women and 9 men; age range 35 - 66 years with 112 lesions) with lichen planus were enrolled. The study covered a three-month period of therapy by IMOD (400 mg/day) and a three-month follow-up period after drug cessation. Outcome mea- sures include soreness relief based on the “nu-meric scale”, and clinical improvement of lesion size and score. Saliva levels of TNF-α was analysed at the baseline and after treatment by ELISA. Statistical analysis of Wilcoxon and paired student’s t-test were used. Results: Approximately 85% of patients showed partial to complete improvement and re-mained sym- ptom free after drug cessation. There was no signifi-cant difference in mean saliva TNF-α level before and after the treatment. Conclusion: These results suggest that IMOD seems to be an effective alternative treat- ment for OLP and TNF-α may not be a good indica- tor for monitoring therapeutic response of OLP.